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Cognitive training for freezing of gait in Parkinson’s disease: a
randomized controlled trial
Courtney C. Walton 1, Loren Mowszowski1,2, Moran Gilat1, Julie M. Hall1,3, Claire O’Callaghan1,4, Alana J. Muller1,
Matthew Georgiades1, Jennifer Y. Y. Szeto1, Kaylena A. Ehgoetz Martens1, James M. Shine1,5, Sharon L. Naismith1,2 and
Simon J. G. Lewis 1
The pathophysiological mechanism of freezing of gait (FoG) has been linked to executive dysfunction. Cognitive training (CT) is a
non-pharmacological intervention which has been shown to improve executive functioning in Parkinson’s disease (PD). This study
aimed to explore whether targeted CT can reduce the severity of FoG in PD. Patients with PD who self-reported FoG and were free
from dementia were randomly allocated to receive either a CT intervention or an active control. Both groups were clinician-
facilitated and conducted twice-weekly for seven weeks. The primary outcome was percentage of time spent frozen during a Timed
Up and Go task, assessed both on and off dopaminergic medications. Secondary outcomes included multiple neuropsychological
and psychosocial measures. A full analysis was first conducted on all participants randomized, followed by a sample of interest
including only those who had objective FoG at baseline, and completed the intervention. Sixty-five patients were randomized into
the study. The sample of interest included 20 in the CT group and 18 in the active control group. The primary outcome of
percentage time spent frozen during a gait task was significantly improved in the CT group compared to active controls in the on-
state. There were no differences in the off-state. Patients who received CT also demonstrated improved processing speed and
reduced daytime sleepiness compared to those in the active control. The findings suggest that CT can reduce the severity of FoG in
the on-state, however replication in a larger sample is required.
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INTRODUCTION
Freezing of gait (FoG) is a disabling symptom of Parkinson’s
Disease (PD), which presents as a “brief, episodic absence or
marked reduction of forward progression of the feet, despite the
intention to walk”.1 FoG is well-known to lead to falls2 and lower
quality of life, making it an important target for treatment.3 The
pathophysiological mechanism of FoG has been linked to
executive dysfunction, particularly in aspects of cognitive
control,4 which aligns with neuroimaging evidence showing
fronto-parietal and fronto-striatal impairments.5 Recent meta-
analytic data suggests that cognitive training (CT) is an
effective6 and important7 behavioral intervention for improving
cognition, and in particular executive functions, in patients
with PD.
Given that these executive deficits have been hypothesized to
underlie the pathophysiological mechanisms of FoG, it is plausible
that reducing executive dysfunction via CT may lessen the severity
of FoG, by mediating more effective fronto-striatal function.8 A
number of studies have now shown that CT in PD can lead to
neuroplastic changes by way of increased activity and functional
connectivity in frontal-striatal regions.9–11 Given that FoG relates
to dysfunction in these areas, it is reasonable to hypothesize that
CT may facilitate more efficient processing between frontal and
striatal regions, leading to a reduction of FoG severity. Interested
readers are directed to a previous review from our group, which
has provided more extensive evidence and rationale for this
proposal.12
In this study, a double-blind randomized controlled trial was
conducted to explore the efficacy of CT targeting executive
functions in PD patients with FoG. We hypothesized that
participants receiving CT would show improvements as illustrated
by the reduced severity of FoG after completion of the
intervention. Additionally, we anticipated that secondary out-
comes including cognitive and psychosocial measures would
show improvement following the CT program.
RESULTS
Participants
Figure 1 illustrates the flow of participants moving through the
study. The first participant was randomized in April 2013 and the
last in June 2015. There were nine dropouts in the active
control condition (AC) (five prior to beginning the program) and
one participant was lost to follow up. There were no dropouts in
the CT group. In addition, in the AC group one participant was
removed entirely from the analysis as their diagnosis was
changed from PD to Progressive Supranuclear Palsy, and a
second was removed as they could not complete the TUG
assessments due to severe motor disability. Two participants
were removed from the CT group due to inadvertent
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incorrect randomization. These participants were retrospec-
tively identified as not meeting the original inclusion criteria and
thus it was determined their data would not be analysed at
any point.
Upon intervention completion, TUG scoring indicated that
despite self-reporting FoG, nine participants from the CT and four
from the AC group did not objectively exhibit FoG on baseline
assessment. Therefore, we designed two analysis populations
Fig. 1 CONSORT Flow diagram
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post-hoc. The full analysis set (FAS) included all participants
randomized into the study, whether or not they dropped out, or
showed objective FoG at BL. The sample of interest set (SIS) was
decided upon as a post-hoc analysis, to account for the fact that a
number of participants did not display FoG at baseline. The SIS
therefore included only those participants who showed objective
FoG on BL testing, as identified in the baseline TUG, and
completed the study in full. The SIS population is considered
the analysis of interest and is therefore what is reported in the
results, however all analyses were initially run on the FAS sample
to confirm no sampling bias. Demographic data for both the FAS
and SIS samples are provided in Table 1.
Primary outcome
Results of the SIS analysis for the primary outcome are displayed
in Table 2. This analysis showed that patients in the CT group
showed a large and statistically significant reduction in FoG
severity in the on-state compared to participants in the AC. There
was no difference in the off-state. The FAS analysis was consistent
with these results, suggesting that the SIS sample was not biased.
We did not compare performance across each of the four
conditions separately, on and off as this was not part of the
predetermined outcome plan, and secondly, we felt it was an
inappropriate exploratory analysis given the smaller than antici-
pated sample.
Secondary outcomes
Results of the SIS analysis for the secondary outcomes are
displayed in Table 3. In the SIS analysis, there were no statistically
significant differences for any of the secondary outcomes over
time between groups.
Covariate analysis
The covariate analysis showed that the results for the primary
outcome remained unchanged by the introduction of covariates
(i.e., still statistically significant). However, in terms of secondary
outcomes, the inclusion of DDE as a covariate led to TMT-A and
daytime sleep disturbance scores becoming significant, with those
in the CT group improving compared to the AC.
DISCUSSION
This pilot study represents one of the largest RCTs of CT to date in
PD. Though interpretation of the results must remain cautious
owing to the limitations outlined below, the results allude to the
potential for CT to reduce the severity of FoG in people with PD.
We showed that CT led to a large and significant reduction of FoG
severity compared to AC while in the on-state, but this was not
replicated in the off-state. These results were consistent, whether
we included participants who did not display FoG at baseline or
not, and when accounting for covariates. We suggest these results
warrant larger scale replication, employing the suggested
methodological adjustments we provide below.
The result of FoG only improving during the on-state is
noteworthy. Firstly, we preface this discussion by stating this is
the clinically relevant behavioral state, as patients in their day-to-
day life would take dopaminergic medications as prescribed to
minimize time in the off-state. Our provisional supposition to
explain this result is that participants in the off-state were too
impaired to benefit from any of the potential changes initiated
through CT. Training was expected to impact frontal processing
Table 1. Demographic data of participants in both analysis samples









Gender (M/F) 22/10 21/8 11/7 14/6
Age, years 68.50 (7.5) 68.48 (8.0) 69.61 (7.8) 69.70 (7.6)
Years since
diagnosis
11.06 (6.6) 8.82 (4.9) 11.89 (6.6) 9.95 (4.4)






Education, years 13.97 (3.2) 13.59 (3.2) 14.44 (3.5) 13.55 (3.4)
MMSE 28.16 (1.8) 27.72 (2.0) 28.56 (1.6) 27.35 (2.0)
Sessions
attended
11.58 (3.7) 13.31 (0.9) 13.06 (1.2) 13.4 (0.9)
Days until follow
up
8.91 (6.9) 6.48 (5.6) 9.11 (7.4) 7.20 (5.7)
Has DBS 6 4 3 4
MDS-UPDRS
Motor on
36.16 (13.7) 36.83 (13.3) 33.44 (12.6) 38.70 (13.7)
MDS-UPDRS
Motor off
43.76(11.7) 42.12 (12.4) 43.27 (11.8) 46.13 (10.9)
Hoehn and Yahr stage
1 1 0 1 0
2 12 11 5 5
2.5 6 5 5 5
3 11 9 6 7
4 2 4 1 3
LEDD levadopa equivalence daily dose, MMSE mini-mental state examina-
tion, DBS deep brain stimulation, MDS-UPDRS Movement Disorder Society
Unified Parkinson’s Disease Rating Scale
Table 2. Primary outcome data between groups before and after intervention
AC group CT group Comparison of change
%TF ona
BL 6.61 (3.92, 11.15) 9.16 (5.52, 15.19) 0.3 (0.14, 0.62); T=−3.36; p= 0.002; d= 1.02
FU 11.99 (7.11, 20.23) 4.95 (2.99, 8.21)
Change from BL 1.81 (1.08, 3.05) 0.54 (0.32, 0.90)
%TF offa
BL 16.61 (9.22, 29.93) 8.02 (4.59, 13.98) 1.07 (0.64, 1.76); T= 0.26; p= 0.800; d= 0.08
FU 15.44 (8.57, 27.81) 7.94 (4.55, 13.85)
Change from BL 0.93 (0.64, 1.34) 0.99 (0.70, 1.40)
aAnalysis conducted on Log10 transformed data and represented by geometric means. The change from baseline is a ratio of the geometric means at follow-
up compared with baseline. The comparison of the changes from baseline is the ratio of the change from baseline for the CT group compared the AC group.
95% CIs are presented in brackets. Direction of change and statistical significance was matched in the FAS analysis
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Table 3. Secondary outcome data between groups before and after intervention
AC group CT group Comparison of change
MOCA
BL 25.33 (23.57, 27.09) 24.15 (22.48, 25.82) 0.84 (−1.38, 3.06); T= 0.77;
FU 25.39 (23.63, 27.15) 25.05 (23.38, 26.72) p= 0.45;
Change from BL 0.06 (−1.55, 1.67) 0.9 (−0.63, 2.43) d= 0.24
HVLT-R total
BL 19.39 (16.83, 21.95) 18.50 (16.07, 20.93) −1.93 (−4.75, 0.88);
FU 21.72 (19.16, 24.28) 18.90 (16.47, 21.33) T=−1.39; p= 0.17;
Change from BL 2.33 (0.29, 4.38) 0.40 (−1.54, 2.34) d= 0.44
HVLT-R delayed
BL 5.67 (4.23, 7.10) 5.00 (3.64, 6.36) −0.53 (−2.21, 1.15);
FU 6.35 (4.89, 7.80) 5.15 (4.49, 6.751) T=−0.64; p= 0.53;
Change from BL 0.68 (−0.55, 1.92) 0.15 (−0.99, 1.29) d= 0.19
Digit span total
BL 16.00 (14.41, 17.59) 14.85 (13.34, 16.36) −0.93 (−2.18, 0.32);
FU 16.78 (15.19, 18.37) 14.70 (13.19, 16.21) T=−1.50; p= 0.14;
Change from BL 0.78 (−0.13, 1.69) −0.15 (−1.01, 0.71) d= 0.47
TMT-A timea,b
BL 44.74 (35.40, 56.48) 50.31 (40.10, 63.05) 0.78 (0.64, 0.95);
FU 45.67 (36.14, 57.64) 39.77 (31.65, 49.90) T=−2.57; p= 0.01;
Change from BL 1.02 (0.89, 1.18) 0.79 (0.69, 0.91) d= 0.62
TMT-B timea
BL 119.11 (95.63, 148.31) 136.08 (110.52, 167.51) 0.88 (0.75, 1.04);
FU 120.96 (97.11, 150.61) 122 (99.12, 150.29) T=−1.50; p= 0.14;
Change from BL 1.02 (0.90, 1.15) 0.90 (0.80, 1.01) d= 0.48
VF-phonemic
BL 37.22 (32.26, 42.19) 31.55 (26.84, 36.26) −0.47 (−3.96, 3.03);
FU 37.89 (32.93, 42.85) 31.75 (27.04, 36.46) T=−0.27; p= 0.79;
Change from BL 0.67 (−1.87, 3.2) 0.20 (−2.21, 2.61) d= 0.09
VF-semantic
BL 33.22 (28.46, 37.99) 30.45 (25.93, 34.72) −1.03 (−5.28, 3.23);
FU 34.00 (29.23, 38.77) 30.20 (25.68, 34.72) T=−0.49; p= 0.63;
Change from BL 0.78 (−2.31, 3.87) −0.25 (−3.18, 2.68) d= 0.15
VF-switching total
BL 12.11 (10.54, 13.68) 9.70 (8.21, 11.19) 1.18 (−0.51, 2.87);
FU 11.78 (10.20, 13.35) 10.55 (9.06, 12.04) T= 1.42; p= 0.16;
Change from BL −0.33 (−1.56, 0.89) 0.85 (−0.31, 2.01) d= 0.45
VF-switching accuracy
BL 10.83 (9.04, 12.63) 8.90 (7.20, 10.60) −0.09 (−2.54, 2.35);
FU 10.28 (8.48, 12.07) 8.25 (6.55, 9.95) T= 0.08; p= 0.94;
Change from BL −0.56 (−2.33, 1.22) −0.65 (−2.33, 1.03) d= 0.02
SDMT total
BL 35.44 (30.00, 40.89) 33.95 (28.78, 39.12) 0.47 (−3.74, 4.68);
FU 37.22 (31.77, 42.67) 36.20 (31.03, 41.37) T= 0.23; p= 0.82;
Change from BL 1.78 (−1.28, 4.83) 2.25 (−0.65, 5.15) d= 0.07
AGN latency
BL 595.75 (547.92, 643.58) 657.65 (608.42, 706.89) −29.89 (−66.37, 6.58);
FU 586.42 (538.89, 633.95) 618.43 (569.19, 667.67) T=−1.67; p= 0.10;
Change from BL −9.33 (−34.34, 15.68) −39.22 (−65.78, −12.67) d= 0.62
AGN omissionsa
BL 2.85 (1.49, 4.94) 4.35 (2.42, 7.37) 0.70 (0.46, 1.06);
FU 4.26 (2.42, 7.08) 4.15 (2.29, 7.05) T=−1.73; p= 0.09;
Change from BL 1.37 (1.03, 1.82) 0.96 (0.71, 1.3) d= 0.61
AGN commissionsa
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and also occurred in the on-state. In the dopamine depleted state,
it is conceivable that the striatal dysfunction overshadowed any
benefit of CT,8,13 and FoG could not be improved. Our future
analysis of functional neuroimaging outcomes in this study may
be able to unravel this further.
A number of trials in older adults have now shown that CT can
have a beneficial impact on multiple gait parameters.14–16 In PD
specifically, a pilot study by Milman and colleagues17 showed that
12 weeks of CT could improve TUG performance. Unfortunately,
this pilot study did not employ a control group. Therefore, the
current results are an important extension showing improvements
on TUG performance via the reduction of FoG, compared to an
active control group.
Given that FoG was reduced in the CT group, we expected there
to be additional improvements in tests of EF, which were
presumed to underlie any improvement of FoG. However, changes
on these outcomes did not reach statistical significance. We were
therefore unable to confirm the hypothesis that improving EF
would be the driver of reduced severity of FoG. It is possible that
our smaller sample size was a factor however (though it was
deemed inappropriate to conduct post-hoc power analysis18).
Indeed, there were near medium-sized effect sizes (d ≥ 0.45) for
many of the executive tests we anticipated improvements on
including TMT-B, and shift-measures of the affective go-no-go test
(AGN) and verbal fluency (VF) (see Table 2). We do note however
that when adjusting for the effect of dopaminergic medication,
the CT group did show medium-sized significant improvements
compared to AC in processing speed and daytime sleepiness.
Limitations
This study has limitations which warrant consideration. The first is
that we did not meet the projected sample size target due to
feasibility issues with recruitment. In addition, there were a
number of dropouts in the AC group, although we note that over
half of these dropouts occurred prior to commencement of the
intervention and only one was due a lack of interest. The third
issue was that participants were randomized prior to TUG scoring.
This was necessary to avoid delay to participants being enrolled as
TUG scoring is time consuming, requiring skilled and trained
raters. Nonetheless, we attempted to address these limitations by
running the FAS analysis, which confirmed our primary result.
Additionally, despite random allocation, the groups were
unbalanced in their baseline FoG severity. The CT group had
more FoG than the AC in the on and less in the off-state. We
stratified the randomization by cognitive functioning (MOCA
scores), however it may be more appropriate in future to stratify
by objective FoG scores at baseline. We highlight however that
the results remained when accounting for the impact of LEDD,
and that the on-state is the clinically meaningful state. Related to
this unbalanced severity, it is important to highlight that the AC
group actually had worse FoG at follow-up compared to the CT
group in the on-state and this pattern of results was replicated in
the FAS analysis. Replication with a larger sample is needed to
demonstrate if this is a reliable finding, or represents the variability
found in small samples such as this one.
Table 3 continued
AC group CT group Comparison of change
BL 5.05 (3.35, 7.41) 4.28 (2.76, 6.42) 0.83 (0.54, 1.3);
FU 5.15 (3.45, 7.51) 3.48 (2.19, 5.30) T=−0.83; p= 0.41;
Change from BL 1.02 (0.75, 1.38) 0.85 (0.62, 1.17) d= 0.26
HADS total
BL 10.78 (7.85, 13.71) 12.70 (9.92, 15.48) −1.98 (−5.38, 1.42);
FU 11.56 (8.63, 14.48) 11.50 (8.72, 14.28) T=−1.18; p= 0.25;
Change from BL 0.78 (−1.69, 3.24) −1.2 (−3.54, 1.14) d= 0.37
PDQ-39 total
BL 26.69 (20.81, 32.58) 28.21 (22.63, 33.79) −3.33 (−8.07, 1.41);
FU 27.32 (21.43, 33.20) 25.50 (19.92, 31.09) T=−1.42; p= 0.16;
Change from BL 0.62 (−2.82, 4.06) −2.71 (−5.97, 0.55) d= 0.45
CBI total
BL 18.74 (10.62, 26.86) 33.51 (26.21, 40.81) −4.51 (−10.66, 1.64);
FU 20.85 (12.66, 29.04) 31.11 (23.86, 38.36) T=−1.49; p= 0.15;
Change from BL 2.11 (−2.52, 6.73) −2.4 (−6.45, 1.65) d= 0.53
SCOPA-S dayb
BL 4.77 (3.16, 6.38) 6.31 (4.72, 7.89) −1.66 (−3.27, −0.05);
FU 5.00 (3.39, 6.62) 4.88 (3.32, 6.44) T=−2.10; p= 0.04;
Change from BL 0.24 (−0.91, 1.38) −1.43 (−2.56, −0.29) d= 0.56
SCOPA-S night
BL 5.33 (3.18, 7.48) 6.00 (3.94, 8.06) −0.24 (−2.17, 1.68);
FU 5.61 (3.46, 7.76) 6.03 (3.97, 8.09) T=−0.26; p= 0.80;
Change from BL 0.28 (−1.09, 1.64) 0.03 (−1.32, 1.39) d= 0.06
MOCA Montreal cognitive assessment, HVLT-R Hopkins verbal learning test-revised, WMS-III Wechsler Memory Scale, VF verbal fluency, DKEFS Delis–Kaplan
executive function system, SDMT symbol digit modalities test, TMT trail making test, AGN affective go-no-go test, HADS Hospital Anxiety & Depression Scale,
SCOPA Scales for Outcomes in Parkinson’s disease, PDQ-39 the Parkinson’s disease questionnaire, CBI-R Cambridge behavioral inventory-revised
aAnalysis conducted on Log10 transformed data and represented by geometric means. The change from
baseline is a ratio of the geometric means at follow-up compared with baseline. The comparison of the changes from baseline is the ratio of the change from
baseline for the CT group compared the AC group
bResults are adjusted for DDE as a covariate. 95% CIs are presented in brackets
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Future directions
We believe there is reason to be hopeful for the use of these trials
in the future. Feedback from participants and family members
involved in the groups was overwhelmingly positive, our pilot
results highlight positive trends, and the importance of non-
pharmacological trials including CT has become increasingly
clear.7,19,20 We suggest that replication of this trial is warranted.
However, with the hope of improving any future work learning
from some of the issues that were raised during this study, we
suggest authors consider some of the following suggestions.
Future studies where possible should aim to score FoG severity
prior to enrollment. A certain threshold for severity (e.g., >5%)
should be specified for eligibility, and stratification across groups
could also be based on this. Where possible, additional methods
of FoG measurement could increase the reliability of %FoG scores.
This could be done through measures such as gait mats and
accelerometry data, and also repeat TuG assessments to address
measurement variability. Multisite recruitment would increase the
potential for sample size without relying on home-based CT,
which we do not believe would be a viable option,21 particularly in
this sample. The inclusion of additional data to aid analysis such as
measurement of expectancy effects and CT training data can be
useful. Finally, we did not include a long-term follow up
assessment. This has often been used as a criticism against CT,
though we rebut that very few interventions elicit sustained
improvements after the cessation of treatment. Thus, it is likely
that clinically, CT needs to be continuously delivered in order to
continue any found benefits, just like most other interventions
(e.g., exercise, medications etc). Nevertheless, obtaining a better
understanding of how long such results are maintained22 is useful
for future trial design and clinical applications, and thus future
studies could try to obtain this information if feasible.
CONCLUSIONS
The current study provides preliminary evidence that CT can
reduce the severity of FoG in PD during the on-state. This
improvement was seen without concurrent, significant changes to
executive functioning (despite near-medium sized effects on these
measures), but in the context of improved processing speed and
daytime sleep disturbance. Despite the limitations of this study,
these results add to the growing body of evidence showing that




This study was registered in 2013 on the 5 April through the Australian and
New Zealand Clinical Trials Registry (ACTRN12613000359730) and was
approved by the Human Research Ethics Committee of the University of
Sydney. Written informed consent was obtained from all participants.
Eligibility
Eligible participants were those diagnosed with idiopathic Parkinson’s
disease based on the UK Brain Bank clinical criteria,23 with self-reported
FoG at the time of assessment, and who were free from dementia as
determined by a score of ≥24 on the mini-mental state examination
(MMSE).24
Recruitment
The study was advertised in a local PD community magazine as well as
local PD community support groups. Potential participants were also
recruited from the Parkinson’s Disease Research Clinic at the Brain and
Mind Centre, University of Sydney. Interested participants were invited to
participate if they had previously reported a positive score on Question 3
of the Freezing of Gait Questionnaire (FOG-Q): “do you feel that your feet
get glued to the floor while walking, making a turn, or trying to initiate
walking (freezing)?”.25
Prior to recruitment, we used baseline data from a previously published
trial26 to conduct a power analysis using a conservative effect size estimate
of at least 0.2 in the study’s primary outcome. This suggested the minimum
sample size required for each group was 39 (based on power= 0.80 and α
= 0.05).
Study design
The study was a double-blind randomized active controlled trial. Interested
patients were enrolled by CCW and LM after they met eligibility criteria
during a baseline assessment and were then randomized into either the CT
or an AC group. Conditions were masked as either “morning” or
“afternoon” sessions, and the order of these was randomized between
recruitment waves prior to trial commencement. In order to facilitate
blinding, participants were told that each session involved different
computerized activities, but were not explicitly told of a treatment or
control group. Randomization of participants and morning/afternoon
sessions was carried out using a randomly generated number sequence
allocated by a blinded researcher not involved in trial recruitment, data
gathering, assessments or training. Randomization was undertaken using
permuted blocks and stratified by cognitive functioning, with strata
defined by Montreal cognitive assessment (MOCA) scores of <26 or ≥26.
Participants were advised of their allocation into the morning or afternoon
session by way of sealed opaque envelopes delivered by CCW upon
completion of the baseline assessments. Post-intervention assessments
were conducted by clinicians who were blinded to treatment allocation. All
participants allocated to the AC group were offered the opportunity to
complete CT after their involvement in the trial was complete. Ten
participants elected to complete this, with those who declined citing time
commitments as the primary reason.
Assessments
Baseline and post-intervention assessments were each completed in two
parts: on and off-medications. The on-state assessment included a
neuropsychological test battery, psychosocial measures, part III of the
Movement Disorders Society’s revision of the Unified Parkinson’s Disease
Research Scale (MDS-UPDRS),27 and a modified timed up-and-go (TUG)
task. These assessments were completed in a random counterbalanced
order and took approximately 2.5 h to complete. Baseline assessments
were conducted within 3 weeks prior to training commencement, and
follow-up assessment was within 3 weeks of the intervention finishing.
The practically defined off-state assessment was completed in the
morning on a different day when participants were asked not to take
their usual Parkinson’s medication until after the assessment, and
comprised a repeated MDS-UPDRS part III and TUG, taking approximately
1 h. Those with deep brain stimulation did not complete the off-state
assessment. A random subset of participants also underwent neuroima-
ging, however the investigation of any training-induced changes are a
tertiary outcome and are therefore not included in the current
manuscript.
Primary outcome
The primary outcome was percentage of time spent frozen (%TF) across all
four trials of a TUG assessment. Percentage was chosen as the primary
outcome as it was anticipated to be more sensitive than a reduction on the
FOG-Q, whilst accounting for inter-individual variability in gait speed and
the variable duration of freezing episodes across TUG tasks.26 In each task,
the participant was requested to get up from a chair, walk to a square box
shape taped to the floor five meters ahead and complete both a left and a
right turn (see Fig. 2). TUGs were video recorded and then scored
independently post-assessment. Six scorers (MG, JMH, AJM, MG, JYYS, and
KAEM) were randomly distributed videos of the TUGs. Scorers were given
baseline and follow-up TUG videos in a random order for the same
participant, to minimize pre-post scoring variability. FoG was tagged in the
video at any point when a participant made a paroxysmal and involuntary
cessation of normal progression of the feet through the task. This included
a typical trembling of the feet, short shuffling steps of a few centimetres in
length or a complete motor block.28
The %TF outcome was calculated by summing all FoG episodes across
the four conditions, and dividing by the total time to complete across all
conditions. Inter-rater variability amongst blinded scorers was strong, and
calculated by all scorers being given a random selection of the same six
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videos to independently score. The intraclass correlation coefficient was
.902 across all FoG episodes (average %TF: 9.56%). We note that two of the
six videos by chance did not contain FoG, however they were included to
confirm no false-positive scoring had occurred. As this inflated reliability
across scorers however, we re-calculated the coefficient with the two
videos removed to be sure. Scoring was still accurate across raters (.865)
(average %TF: 14.31%).
Secondary outcomes
Cognitive assessment. To assess global functioning for descriptive
purposes, the MMSE24 and MOCA29 were used. Total and delayed Hopkins
verbal learning test-revised scores were used to assess verbal memory.30
To assess attention and working memory, the total score from the Digit
Span subtest of the Wechsler Memory Scale was used.31 To assess verbal
fluency, the total words generated on each condition of the VF subtest of
the Delis–Kaplan executive function system was used.32 In this test, part 1
measures phonemic fluency across three letters, part 2 measures semantic
fluency across two categories while parts 3 and 4 assess switching
between two differing categories. Part 3 represents the total number of
correct items, while part 4 represents the total number of correct switches.
Processing speed was assessed by the number of correct responses on the
oral symbol digit modalities test.33 For these measures, higher scores are
indicative of better performance.
To assess processing speed and cognitive flexibility, times for parts A
and B respectively of the trail making test (TMT) were used.34 Finally, the
AGN of the Cambridge neuropsychological test automated battery35 was
used as a computerized measure of inhibitory control/switching. Mean
latency post-switch was used to determine performance in addition to the
number of commissions or omissions. For these tests, lower scores were
indicative of better performance. Alternate versions of each test with the
exception of Digit Span (not available) were used at baseline and follow-up
to minimise potential practice effects.
Psychosocial measures. Participants completed several questionnaires
targeting mood and wellbeing. The Hospital Anxiety & Depression Scale
was used to assess anxious and depressive symptoms.36 The Scales of
Outcomes in PD (SCOPA)-Sleep was used to assess sleep quality in terms of
both daytime sleepiness and night time sleep disturbance.37 The
Parkinson’s Disease Questionnaire (PDQ-39)38 was used as a measure of
quality of life. Finally, if a participant lived with a carer, the Cambridge
behavioral inventory-revised39 was used as an informant report of
cognitive and behavioral changes. For all of these scores, a higher score
was indicative of more substantial impairment.
Intervention. Both the CT and AC groups attended sessions at the Brain
and Mind Centre at the University of Sydney in our designated CT
laboratory, and both conditions were matched in terms of time, clinician
contact, computer use and social interaction. In accordance with our
previous CT programs for older adults (see,40,41) the intervention was
completed in a group format (n ≤ 10), and comprised of 2-h sessions, twice
weekly over 7 weeks (14 sessions in total). Both groups were supervised
and facilitated by CCW & LM. The first hour of the session was identical
across CT and AC groups: (i) 30–45min was designated to psycho-
education on a number of topics relevant to PD including cognition, sleep
and mood, and was delivered by multidisciplinary specialists and
researchers from the Brain and Mind Centre; (ii) participants then took
an enforced break of 10–15min. This first hour, whilst not CT per-se, was
included for both conditions as a means of increasing participant
engagement and has previously been shown to support our excellent
program adherence rates.40,41 The second hour of the session differed
across CT and AC groups:
(A) CT: Participants in this group completed a program of computerized
CT tasks, selected for their focus on executive functions and on the basis of
our previous experience employing the “Neuropsychological Educational
Approach to Remediation” approach41,42 in providing computerized CT to
>400 older adults,41,43,44 including those with PD.40 Tasks included
designated “brain training” programs (e.g., Attention Process Training-
III45) as well as commercially-available software (e.g., computerised
Sudoku), which were determined by clinical neuropsychologists (LM,
SLN) to target the cognitive processes of most interest to FoG (inhibitory
control, attentional set-shifting, working memory, processing speed and
visuospatial skills).4,12 Performance was monitored by the facilitators, with
the focus of progressively making the tasks more difficult where possible
for the participant. These changes were done in an individualized manner
based on performance and in consultation with the participant. Therefore
while the tasks delegated for each session where standardized across all
participants, there were differences in how far each progressed in terms of
difficulty. The majority of exercises provided the participant with feedback
in the form of scores, and this was further discussed between facilitators
and participants to help them better understand their performance.
(B) AC: Participants in this group completed a series of non-specific
computer-based tasks including predominantly watching informative
nature videos and answering content-related questions as previously
Fig. 2 Each condition involved two trials with a left and right turn version. In the 180° condition, the participant walked to the box, turned
around and returned to their chair; In the 540° condition, they completed a 540° turn in the box before returning to the chair; In the box
condition, participants shuffled around the box, keeping their inside foot to the outside of the box; in the dual task condition, participants did
the same as in the 180°, however completed a cognitive task as they walked. This was either naming the months backwards or multiples of 9
or 7 aloud. The %TF outcome was calculated by summing all FoG episodes across the four conditions, and dividing by the total time to
complete across all conditions
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used,46 as well as online “treasure hunts” devised by our team. These tasks
were designed to provide broader, generalized cognitive engagement
compared to the targeted focus on specific cognitive functions in the CT
condition. Therefore, those in this group were not expected to have
reduced FoG severity but were rather intended to match for clinician and
peer contact, along with computer use.
Statistical analysis. To minimize any potential bias, statistical analyses
were conducted by a consultant statistician experienced in RCTs who was
based at the University of Sydney (see acknowledgements) and who was
not involved in any other aspect of the trial. Data was analysed using SAS
software version 9.4.
The analysis took the form of a mixed effects model using fixed effects
fitted to all endpoints, to test the null hypothesis of no difference in
change over time across groups against the alternative hypothesis of a
difference between the two arms. An additional term in the model was
fitted to account for the repeated measures pre- and post-intervention.
“Participant” was declared a random effect. An unstructured covariance
pattern between baseline and post-intervention was used. The Kenward
and Roger’s method for correcting for the fixed effects, standard error bias
by inflation of the variance and Satterthwaite’s adjustment to the degrees
of freedom has also been applied to cater for the small sample size.
Analyses of endpoints with non-normal variance for analysis have been
transformed to the log10 scale for analysis. Results were back transformed
for interpretation and represent geometric means. Cohens d was
calculated as a measure of effect size with 0.2, 0.5, and 0.8 considered
small, medium and large effects in the CT compared to the AC group.47
Covariate analysis. An additional analysis was undertaken to investigate
the effects of the following covariates on all outcome measures: age,
education, levodopa equivalency daily dose LEDD;48 years since diagnosis,
and the amount of days between CT completion and FU assessment (days
until FU) on each outcome. Only significant results are reported.
Data availability statement
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
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